Celltrion Shares Recent Biosimilar Development News

Goodwin
Contact

Goodwin

Celltrion Healthcare announced last week that it received positive results from the Phase III trial of its high-concentration, low-volume, citrate-free adalimumab biosimilar, CT-P17 or Yuflyma™, in patients with active rheumatoid arthritis (RA).  According to the press release, “[r]esults demonstrated comparable efficacy in terms of ACR20/50/70 response rates, both in patients receiving maintenance therapy and in patients switched from reference adalimumab to CT-P17 up to week 52.”

In the same press release, Celltrion also announced that the European Commission has granted marketing authorization for Celltrion’s subcutaneous infliximab biosimilar, Remsima™ SC (CT-P13 SC), for new and existing RA patients.  Celltrion Healthcare Canada Limited announced this week that it has launched Remsima™ SC in Canada for the treatment of adult patients with RA.  Jovan Antunovic, Commercial Director at Celltrion Healthcare Canada, noted that Celltrion is  “delighted to be able to launch Remsima™ SC …and to bring the first and only subcutaneous form of infliximab to patients, payers and clinicians in Canada.”

Celltrion also announced this week that it has acquired a controlling stake of Iksuda Therapeutics, a British antibody-drug conjugate (ADC) developer.  Celltrion said it “was looking for a business model that could generate revenue and value from products other than biosimilars and chemical drugs,” and, “[a]gainst this backdrop, we decided to invest in Iksuda, which specializes in ADC, as it can create synergy with Celltrion’s antibody treatments.”

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.